🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How to discern important new data @asco? Look beyond data that repackages known truths but do NOT really advance our understanding Common examples: 1. Less cancer is better than more cancer 2. Responders do better 3. More treatments vs. less improves PFS Happy #ASCO25

At the upcoming #ASCO25 mtg there will be an abundance of #QOL data 📊 - some of it in the context of ⬆️ high objective measures of toxicity 🤢🥴🫩 It may be worth hearing this FDA Oncology perspective on #QOL measures as it it relates to #toxicity from a recent #ODAC mtg

🆕article in press: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial tombal, silke gillessen, EORTC tinyurl.com/bdhhv78u

“These findings indicate that #BCL-XL inhibitors may be effective…in… tumors with #RB1 loss, & that pharmacological induction of replication stress may be a broadly applicable approach for sensitizing to BCL-XL inhibitors.” ⁦Adam Sharp⁩ nature.com/articles/s4146…

Important new data from ESMO - Eur. Oncology last fall now in print! #Radium #Enzalutamide #Peace3 There should be more discussion on how this data could impact #ProstateCancer and the current treatment landscape.

The Rare Cancer Research Foundation + Pattern.org is hiring a Chief of Staff - please share with those who may be a good fit and are passionate about this important mission. linkedin.com/jobs/view/4237…

Updated data from #PSMA monitoring study in #BCR #ProstateCancer ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

😜

Join ⁦Dr. Karen Winkfield⁩ ⁦Nina Shah⁩ Dr.Van Loon Dr. Rathmell in the Women’s Working Center at 9:15 to listen to their career journey transitions!! ⁦ASCO⁩ #asco25

What should we do for #ProstateCancer patients with #PSMA+ #BCR? While we can use any treatment do we NEED to? Stop by tomorrow abstract BD# 297. Monday 9am-noon The answer is pretty clear… #ASCO25 ASCO National Cancer Institute

The testis cancer educational section at #ASCO2025 is going to be great! Come and attend! Hall D1 at 1:15 today June 2/2025. I am honoured to be part of this stellar panel: Dr Einhorn, Dr Haugnes, DrBagrodia

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

Great discussions @asco #ProstateCancer posters #ASCO25 #PSMA+ #BCR is an indolent process & pts do NOT require urgent therapy in most cases We should be ⚠️ cautious about over-treatment 🔗shorturl.at/NtxdF Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs Did we lower standard to PFS when both agents are approved for mCRPC? 🤔 #ProstateCancer #ASCO25 nature.com/articles/s4158…

Most expected #Arches 5 yr follow up data to be pro-forma @asco #ASCO25 But then this data popped up 👀 Less clear benefit of Enza+ADT in low volume #mCSPC Should this raise ?s for #mCSPC intensification w/#parp & #LU-psma Implications for over treating PSMA+ recurrence?

It remains disappointing that (unlike the Lu-PSMA trials) the #PARP inhibitor trials do not include cross over and thus continue to leave the key question of sequence unanswered. This limits understanding of clinical optimization #AMPLITUDE #ASCO25 @asco

Ravi A Madan M.D. ASCO Agree, the lack of crossover will be debated and is a barrier for early adoption and rapid dissemination of PARP for mHSPC. From what I can find, TALAPRO-3 does not have crossover either.